Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eCas12f1 (enhanced Cas12f1) is an engineered, miniature CRISPR-based genome editing system derived from the Un1Cas12f1 protein. Developed by researchers at Korea University, it is approximately 2.6-fold smaller than SpCas9, which facilitates more efficient cellular delivery via size-constrained viral vectors such as adeno-associated virus (AAV). The system was optimized through a multilayered engineering approach that introduced specific protein mutations (D143R, T147R, K330R, G181R, and S426G) to strengthen nucleic acid interactions within the DNA-binding pocket and incorporated a modified sgRNA with a stable UUCG RNA hairpin to improve structural stability. eCas12f1 demonstrates robust genome editing activity comparable to larger nucleases like SpCas9 and AsCpf1 and is compatible with advanced applications including base editing (adenine and cytosine base editors) and transcriptional regulation, making it a versatile platform for next-generation therapeutic genome engineering.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eCas12f1.